← Back to Screener
Jade Biosciences, Inc. Common Stock (JBIO)
Price$22.85
Favorite Metrics
Price vs S&P 500 (26W)142.90%
Price vs S&P 500 (4W)53.72%
Market Capitalization$1.13B
Indicated Dividend Yield (Annual)0.00%
All Metrics
Book Value / Share (Quarterly)$6.74
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.92
Price vs S&P 500 (YTD)43.95%
EPS (TTM)$-5.40
10-Day Avg Trading Volume0.69M
EPS Excl Extra (TTM)$-5.40
EPS (Annual)$-4.06
ROI (Annual)-38.32%
Cash / Share (Quarterly)$6.82
ROA (Last FY)-36.43%
EBITD / Share (TTM)$-3.05
ROE (5Y Avg)-50.48%
Cash Flow / Share (Annual)$-1.92
P/B Ratio3.39x
P/B Ratio (Quarterly)2.13x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-8.23x
ROA (TTM)-42.99%
EPS Incl Extra (Annual)$-4.06
Current Ratio (Annual)21.09x
Quick Ratio (Quarterly)20.33x
3-Month Avg Trading Volume0.42M
52-Week Price Return-75.64%
Revenue / Employee (TTM)$0
52-Week High$100.10
EPS Excl Extra (Annual)$-4.06
26-Week Price Return151.65%
Quick Ratio (Annual)20.33x
13-Week Price Return55.87%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)21.09x
Enterprise Value$1,038.439
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.82
3-Month Return Std Dev71.08%
Net Income / Employee (TTM)$-2
ROE (Last FY)-38.32%
EPS Basic Excl Extra (Annual)$-4.06
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.40
ROI (TTM)-46.55%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-110.73%
Year-to-Date Return48.09%
5-Day Price Return23.58%
EPS Normalized (Annual)$-4.06
ROA (5Y Avg)-46.71%
Month-to-Date Return62.63%
EBITD / Share (Annual)$-3.62
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-50.48%
EPS Basic Excl Extra (TTM)$-5.40
P/B Ratio (Annual)2.13x
Book Value / Share (Annual)$6.74
Price vs S&P 500 (13W)53.00%
Beta1.36x
Revenue / Share (TTM)$0.00
ROE (TTM)-46.55%
52-Week Low$6.57
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.46
4.43
4.43
4.44
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
JBIOJade Biosciences, Inc. Common Stock | — | — | — | — | $22.85 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Jade Biosciences develops immunotherapies targeting autoimmune diseases using antibody-based approaches. The company's lead candidate, JADE-001, targets the APRIL pathway for IgA nephropathy treatment and is advancing toward clinical-stage development. Jade maintains two additional antibody programs in preclinical development and was founded using technology licensed from Paragon Therapeutics.